Navigation Links
Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Date:3/18/2008

BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) issued the following statement regarding today's indictment of a former employee in connection with the promotional activities for Actimmune(R) (interferon gamma-1b) during a period that ended in June of 2003.

"Today's indictment concerns conduct by a former employee who left the company more than four years ago.

"In 2006, InterMune settled all government claims related to that conduct, without criminal sanctions against the company. At the time, the government acknowledged that InterMune fully cooperated with its investigation and had instituted numerous and comprehensive compliance changes before the investigation even began. Today's government action does not affect the Company's settlement in any way.

"In today's action, the government is bringing charges against a former employee, not against InterMune, its current employees or its Directors.

"Since 2004, InterMune has been a transformed company with a new management team, a rigorous compliance program and a promising pipeline focused on serious pulmonary and hepatic diseases.

"We have taken great strides to put this matter behind us and have focused our resources on what we believe is a promising future for our Company and our shareholders."

The individual charged today was Scott Harkonen, formerly President, Chief Executive Officer and a Director of InterMune.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (H
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
2. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
8. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
9. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
10. Smithfield Foods, Inc. Statement Regarding Animal Cloning
11. Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Reed Technology and Information Services Inc. ... and submission to the U.S. Food and Drug Administration ... Distribution Report (LDR) service for manufacturers of biologics, including ... FDA’s new rule on electronic submission of LDRs. ... and timing of particular biologics introduced to the marketplace, ...
(Date:4/17/2015)... YORK , April 17, 2015  Guggenheim Securities, ... Partners, today announced the hiring of William Tanner ... analyst. Mr. Tanner will start work at ... New York office. "Bill brings ... academic research, to our experienced and highly acclaimed healthcare ...
(Date:4/17/2015)... TX (PRWEB) April 17, 2015 ... and proteomics technologies, announced today that it is ... system, an innovative multiplex PCR based targeted sequencing ... resolution sequence analysis, that enables accurate detection of ... Relay-PCR™ and Omega-Primer™ technologies. The company will collaborate ...
(Date:4/16/2015)... OSAKA, Japan , April 16, ... (CiRA) of Kyoto University and Takeda Pharmaceutical Company ... together to develop clinical applications of induced pluripotent ... diabetes mellitus, neurological disorders and cancer immunotherapy. The ... is designed to expedite multiple research projects for ...
Breaking Biology Technology:Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
... crystals of a pharmaceutical product can allow the medication to ... not soluble in water. Research suggests that more than ... industry dissolve only very weakly in water, if at all. ... it means they are not effective if taken by mouth. ...
... 6 CoreLab Partners , Inc, the global entity ... February of this year, has recently completed the first ever ... the Asia Pacific Rim and the first TQT study for ... pleased to announce that we have recently completed the first ...
... 6 Sangart, Inc., today announced that it has ... Department of Defense to support the development of its ... investigational biopharmaceutical product designed to enhance the perfusion and ... to the capillaries in severely injured trauma patients. This ...
Cached Biology Technology:Nano drugs 2CoreLab Partners Completes First TQT Study in Japan 2Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma 2
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... European Alps suggests that population declines to be observed ... effects of recent climate warming on mountain plants. A ... Department of Conservation Biology, Vegetation and Landscape Ecology of ... to predict migration of mountain plants which explicitly takes ...
... LSU,s Mark Batzer, along with research associate Jerilyn Walker ... modern-day orangutans are host to ancient jumping genes called Alu, ... was done in collaboration with the Zoological Society of San ... is featured in the new open access journal Mobile ...
... requirement for efficient mosquito mass-rearing technology has been one ... of the Sterile Insect Technique (SIT) against mosquitoes. ... next issue of the Journal of Medical Entomology ... Organization (FAO) and the International Atomic Energy Agency (IAEA) ...
Cached Biology News:European mountain plant population shows delayed response to climate change 2LSU research finds orangutans host ancient jumping genes 2
... Hybrid-Ready Tissues are selected tissues from ... been fixed, embedded in paraffin, sectioned and ... the slides are ready for use in ... The Hybrid-Ready tissue slides are suitable for ...
MHC Volumes 1 & 2...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Biology Products: